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Objective: The prognosis for patients with primary cardiac sarcoma is poor. Median
survival is less than 10 months, especially when complete surgical excision is not
feasible. Removal of all cardiopulmonary structures involved by tumor followed by
orthotopic allotransplantation has been proposed to improve long-term survival.
Methods: From 1996 through 1999, we performed combined heart and lung resec-
tion followed by en bloc heart and bilateral lung transplantation in 4 patients (2 men
and 2 women): 2 with inoperable pulmonary arterial sarcoma and 2 with left atrial
sarcoma extending into the pulmonary vein.
Results: Median age at diagnosis was 39 years (range 37-45 years). All 4 patients
were given chemotherapy before transplantation: doxorubicin and ifosfamide in 2
cases, and doxorubicin, ifosfamide, mesna, and dacarbazine in 2 cases. There were
no operative deaths. Median survival after transplantation was 31 months (range
5-49 months). All patients had tumor recurrence: local recurrence in the chest (n 
1) and distant metastases in the brain (n  2) and abdomen (n  1). One patient
remains alive 49 months after disease progression with cerebral metastasis as the
only site of recurrence treated with whole-brain irradiation, resection, and stereo-
tactic radiosurgery.
Conclusions: Combined heart and lung transplantation is a technically feasible
treatment for highly selected patients with localized advanced primary cardiac
sarcomas. The high incidence of metastatic disease, however, limits its utility.
Primary cardiac sarcomas are rare clinical entities,1,2 with an incidenceat autopsy of 0.0001%.3 Soft tissue sarcoma is the most commonmalignant neoplasm of the heart, pericardium, and great vessels.4,5These tumors usually cause symptoms as a result of anatomic ob-struction of blood flow, necessitating resection to relieve symptomsand prevent early death.6
Outcomes after treatment of primary cardiac sarcoma have been extremely poor,
especially when surgical excision is not feasible.5,7,8 In these instances, median
survival is generally 10 months or less.8-10 There are no proven benefits to chemo-
therapy and radiotherapy.5
In a few cases, a curative surgical approach consisting of cardiectomy followed
by orthotopic transplantation has been attempted to provide long-term survival, but
only anecdotal reports of this aggressive approach were available for review.1,11-19
These reports have dealt with transplantation of the heart only, rather than the heart
and lungs. In general, favorable results have occurred only when the cardiac surgical
margins were free of tumor. If the surgical margins were involved with tumor,
disease progression and death ensued despite adjuvant chemotherapy.
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In 1996, we began to investigate whether combined heart
and lung resection followed by en bloc heart and bilateral
lung transplantation might be curative in those instances of
primary cardiac sarcomas in which the tumor clearly ex-
tended beyond the cardiac borders of cardiectomy. During
the next 2 years, we performed this procedure in 4 patients,
2 with inoperable pulmonary arterial sarcomas and 2 with
left atrial sarcomas extending into the pulmonary veins.
Clinical Summaries
Case 1
A 40-year-old previously healthy man reported dyspnea and he-
moptysis. Chest radiography showed a left hilar mass. During
thoracic exploration, an intimal sarcoma of the pulmonary artery
was diagnosed. The patient underwent left pneumonectomy, re-
section of the pulmonary valve and pulmonary artery, and insertion
of a pulmonary homograft from the right ventricular outflow tract
to the right pulmonary artery. Tumor was present in the margins of
the resection. He received 2 cycles of chemotherapy with mesna,
doxorubicin, ifosfamide, and dacarbazine and radiation therapy.
He was referred for consideration of possible heart-lung transplan-
tation. Preoperative scans of head, chest, abdomen, pelvis, and
bone showed no evidence of metastatic tumor. Two months after
referral, the patient underwent combined heart and lung transplan-
tation. Pathologic examination revealed intimal sarcoma in the
right ventricular endocardium and right pulmonary artery. There
were no signs of pulmonary parenchymal metastasis. The postop-
erative recovery was uneventful. After discharge, the patient re-
gained excellent exercise tolerance and returned to full-time em-
ployment. Three years after transplantation, he reported severe
abdominal pain, and small-bowel obstruction was diagnosed. Ex-
ploratory laparotomy demonstrated intussusception of the jejunum
with two polyploid lesions serving as lead points. Resection of the
lesions demonstrated intimal sarcoma identical to the previous
pulmonary artery tumor. The patient was treated with ifosfamide
chemotherapy and sequentially with two investigational drugs,
temozolomide and the cell surface phospholipase inhibitor CT
2584 (Cell Therapeutics Inc, Seattle, Wash). However, he contin-
ued to have extensive abdominal pain and only minimal tumor
regression. The patient died 4 years after transplantation of mas-
sive intra-abdominal tumor bleeding.
Case 2
A 39-year-old previously healthy woman had dyspnea and chest
pain, and pulmonary arterial thrombosis was diagnosed. She un-
derwent thromboembolectomy, which revealed spindle cell sar-
coma of the pulmonary artery extending into both right and left
lobar arteries. The patient underwent 6 cycles of doxorubicin and
ifosfamide chemotherapy after the operation. She was referred for
heart-lung transplantation. Preoperative scans revealed no evi-
dence of disease at the time of listing. However, on the day before
transplantation, she reported weakness in her left hand. Magnetic
resonance imaging of the brain was performed at her local insti-
tution. On the following day, she underwent heart-lung transplan-
tation. Pathologic examination revealed a long, fimbriate tumor
extending into both pulmonary arteries. The results of the magnetic
resonance imaging, which became known after the operation,
showed a 2-cm lesion in the left frontal cortex and a second,
smaller lesion in the cerebellum. The patient’s postoperative re-
covery was without complication, and on the 10th postoperative
day she began whole-brain radiation. Two months after transplan-
tation, she underwent left craniotomy for resection of the parietal
tumor. Subsequently, the patient underwent stereotactic focus ra-
diosurgery for the right cerebellar lesion. She resumed full-time
activities with excellent exercise tolerance. She has had minimal
residual neurologic deficits related to the craniotomy. At present
(49 months after transplantation), the patient remains alive with
cerebral metastasis as the only site of tumor recurrence. Four years
after transplantation, dyspnea on exertion developed, and bronchi-
olitis obliterans syndrome has been diagnosed.
Case 3
A 37-year-old previously healthy woman had dyspnea on exertion
and hemoptysis. Chest radiography showed a large left infrahilar
mass. She underwent exploratory left thoracotomy. There was a
large tumor arising in the left atrium and extending into the left
pulmonary veins. The pathologic examination confirmed a high-
grade spindle cell sarcoma. The patient completed 5 cycles of
chemotherapy with mesna, doxorubicin, ifosfamide, and dacarba-
zine and was referred for heart-lung transplantation. Preoperative
scans showed no evidence of distant tumoral spread. Four months
after listing, she underwent heart-lung transplantation. At the time
of transplantation, a large tumor mass extended from the left
atrium into the left pulmonary veins, into the left lung, and nearly
out to the pleural surface of the left lung. The tumor was removed
en bloc, but function of the left hemidiaphragm was sacrificed. The
immediate postoperative course was complicated by poor clear-
ance of secretions in the left lower lobe. After discharge, the
patient returned to full activity. However, 6 months after the
operation a recurrent tumor mass developed in the left lower lobe.
Biopsy revealed high-grade spindle sarcoma, identical to that
explanted from the heart and lungs. The patient underwent left
lower lobectomy with rib and diaphragm resection. Pathologic
examination showed tumor invasion of the ribs and pleura. After
resection, a course of radiation therapy to the involved site was
completed. The patient subsequently had widespread tumor recur-
rence, including bony metastases. A regimen of monthly pamidr-
onate infusions and thalidomide was commenced. She died of
metastatic disease 16 months after transplantation.
Case 4
A 45-year-old previously healthy man had dyspnea on exertion
and was found to have a large tumor in the left atrium. He
underwent incomplete resection of the tumor, which showed gross
invasion of the left pulmonary vein. Pathologic examination re-
vealed high-grade intimal cell sarcoma. The patient received 4
cycles of doxorubicin and ifosfamide chemotherapy after the op-
eration. Preoperative scans showed no signs of metastatic disease.
The patient was referred for heart-lung transplantation, which he
underwent 2 months after listing. The postoperative course was
complicated by severe reperfusion lung injury and pneumonia. He
was eventually discharged on the 65th postoperative day. He was
readmitted 6 weeks later with symptoms of dyspnea and headache
and was found to have diffuse pneumonitis and a large right
parietal mass. Right craniotomy was performed and showed high-
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grade spindle cell sarcoma identical to the cardiac tumor. After
craniotomy, progressive respiratory failure requiring tracheostomy
developed. The patient died of respiratory failure 5 months after
transplantation. Postmortem examination revealed diffuse pneu-
monitis, alveolar damage, and moderately severe bronchiolitis
obliterans.
Discussion
The 4 case studies presented here indicate that orthotopic
heart-lung transplantation for highly selected patients with
primary cardiac sarcoma is technically feasible. All the
patients had either initially unresectable tumors or persistent
disease after failed attempts at complete resection. To be
considered for transplantation, patients underwent an exten-
sive workup for metastatic disease. Nevertheless, in 1 case
the symptoms heralding the development of cerebral me-
tastases only became apparent the day before transplanta-
tion, and results of magnetic resonance imaging of the brain
from another institution were not available until after the
surgery. All 4 patients had doxorubicin and ifosfamide-
containing regimens before transplantation. All had margins
free of tumor at resection-transplantation.
Despite this dual modality approach, all patients had
progression of disease, at median intervals of 12 months
(range 10-40 months) and 5 months (range 0-34 months)
after diagnosis and transplantation, respectively. Progres-
sion of disease comprised local recurrence in the chest in 1
case, cerebral metastases in 2 cases, and mesenteric recur-
rence in 1 case. Three of 4 patients have died. Median
survivals from diagnosis and transplantation were 39
months (range 11-57 months) and 31 months (range 5-49
months), respectively. Two patients had bronchiolitis oblit-
erans develop after transplantation. There were no episodes
of acute graft rejection.
Primary cardiac sarcoma is the second most common
type of primary cardiac tumor, with myxoma having the
highest incidence.20 Historically, long-term survival of pa-
tients with primary cardiac sarcoma has been poor, with
complete surgical excision often not feasible5,7,8 and no
clearly beneficial role for chemotherapy and radiotherapy.5
Previous anecdotal reports of cardiac transplantation, often
as a therapeutic last resort, have been variable, with both
good outcomes with follow-up of between 8 months and 5.5
years11,12,14,18,20 and poor survivals of between 2 and 9
months.16,17 To our knowledge, this is the first reported
series of cases of combined heart-lung transplantation for
primary cardiac sarcoma. Our experience with these 4 cases
is similar to that seen with cardiac transplantation alone,
with only 1 surviving patient with cerebral metastases at 4.1
years after transplantation.
All patients in this series received doxorubicin-contain-
ing chemotherapy before transplantation. Questions remain
as to the optimal chemotherapy agents (if such agents exist
at all), the number of chemotherapy cycles that should be
recommended before transplantation, and whether addi-
tional chemotherapy should be administered after transplan-
tation to attempt to control metastatic spread of the disease.
Authors of other series of cardiac transplants12,13,14,16 claim
that chemotherapy must be an integral part of the treatment,
but the evidence to support this is not convincing. Despite
chemotherapy, patients with cardiac sarcoma in these series
died of distant metastatic disease.
The role of transplantation in the treatment of a patient
with a history of cancer remains controversial. One concern
has been the potential for the risk of neoplasia to be in-
creased after transplantation by immunosuppressive ther-
apy. There does appear to be an increased incidence of new
tumors, in particular non-Hodgkin lymphoma and skin car-
cinomas, after transplantation. In a study from the Univer-
sity of Pittsburgh, the incidence of lymphoma was 2.3% in
cardiac allograft recipients, with a 3.8% incidence in recip-
ients of combined heart and lung transplants,21 but the
incidence has been reported as high as 13% in heart recip-
ients and 33% in heart-lung recipients.22,23 The incidence of
skin cancer, especially squamous cell carcinoma, is also
increased, with skin cancer occurring in 10.7% of recipients
of cardiothoracic transplants in an Australian study.24 An
increased incidence of sarcomas (excluding Kaposi sar-
coma) is also observed in transplant recipients relative to the
general population (1.8% vs 0.5%).25 The risk of recurrent
tumor in a patient with a known diagnosis of cancer, not
primary in the heart, after transplantation does not appear to
be increased.18,26 In those cases the tumor cells do not have
direct access to the systemic circulation but must pass
through the lungs. There was a 100% survival rate after
heart transplantation in a series of 11 patients with malig-
nant disease with no evidence of recurrent or metastatic
tumor.18 One of these patients had a cardiac angiosarcoma,
but the follow-up was short at 8 months. Two patients had
previous therapy and a were disease free; 1 had had Ewing
sarcoma and the other had had osteogenic sarcoma. Follow-
ups for these three patients were 9 months, 6 months, and 3
years 5 months, respectively. In the other study, 7 patients
with preexisting malignancies underwent cardiac transplan-
tation, with a 2-year survival of 100%, and at an average
follow up of 31 months only 1 patient has a recurrent basal
cell carcinoma.26 None of these patients had a history of
sarcoma.
In conclusion, our limited experience with combined
heart and lung orthotopic transplantation as an aggressive
approach to the treatment of highly selected patients with
primary cardiac sarcomas is disappointing. The future role
of transplantation for patients with such high metastatic
potential remains unclear. All patients in our series had
metastatic disease develop, and this remains the major ob-
stacle to the utility of this therapeutic intervention.
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